Quarterly report · Q2
8129.TEDINET S100PLCG
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥679.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥620.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥4.1bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥1.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.8bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥6.0bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥5.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥740.6bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥702.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥695.9bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥495.0bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥461.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥245.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥241.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥240.7bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥102.1bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥94.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥97.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥97.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥88.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥10.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥407m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥51.01 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.79 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.39 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.84 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥46.88 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥42.62 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 33.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.5% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥850m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥878m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥478m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥654.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥631.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥23.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥782m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥246m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥708.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥679.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥4.9bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥996m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥45.5bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥45.4bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥5m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥819m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥312m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥597.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥572.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥24.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥667m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥100m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥649.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥620.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥28.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥2.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 580
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)EY新日本有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)野 水 善 之 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)小 川 浩 徳 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)白 鳥 大 輔 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 620845000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 679719000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 1266171000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 4802000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 7392000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 18182000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 3271000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 3598000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 13379000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 4119000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 5656000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 5701000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 240749000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 245642000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 241281000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 695931000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 740650000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 702376000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 46.39 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 51.01 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 189.70 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | 42.62 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | 46.88 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 174.48 | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.3455 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.3313 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.3430 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 11593000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 10693000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 16341000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -1445000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -407000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -11032000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -2202000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -2960000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -4473000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 97124000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 97855000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 90014000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 21.84 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 21.79 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 78270142 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 78270142 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 78270142 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |